Gut-liver axis, nutrition, and non-alcoholic fatty liver disease

Clinical Biochemistry

Volumn 48, Issue 13-14, 2015, Pages 923-930

  Kirpich, Irina A ^a   Marsano, Luis S ^a   McClain, Craig J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Dietary factors; Gut microbiome; Intestinal barrier; Metabolic endotoxemia; Nonalcoholic fatty liver disease

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

DIET; ENDOTOXEMIA; FATTY LIVER; HUMAN; INFLAMMATION; INTESTINE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITION; OBESITY; PATHOGENESIS; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; GASTROINTESTINAL TRACT; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY;

EID: 84952975141     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.06.023     Document Type: Review

References (99)

1. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Ann. Intern. Med. 1997, 126(2):137-145.
2. Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
3. Kelly T., et al. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. (Lond.) 2008, 32(9):1431-1437.
4. Cani P.D., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50(11):2374-2383.
5. Cani P.D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56(7):1761-1772.
6. Backhed F., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(44):15718-15723.
7. Jumpertz R., et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am. J. Clin. Nutr. 2011, 94(1):58-65.
8. Hoverstad T., Midtvedt T. Short-chain fatty acids in germfree mice and rats. J. Nutr. 1986, 116(9):1772-1776.
9. Wolin M.J. Fermentation in the rumen and human large intestine. Science 1981, 213(4515):1463-1468.
10. Muccioli G.G., et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 2010, 6:392.
11. Cani P.D. Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin. Microbiol. Infect. 2012, 18(Suppl. 4):50-53.
12. Dumas M.E., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(33):12511-12516.
13. Wang Z., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472(7341):57-63.
14. Swann J.R., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(Suppl. 1):4523-4530.
15. Jiang C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Investig. 2015, 125(1):386-402.
16. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119(5):1340-1347.
17. Zhu L., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57(2):601-609.
18. Wigg A.J., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48(2):206-211.
19. Sabate J.M., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes. Surg. 2008, 18(4):371-377.
20. Ferolla S.M., et al. The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease. Nutrients 2014, 6(12):5583-5599.
21. Miura K., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139(1):323-334. (e7).
22. Taira R., et al. Bacterial cell wall components regulate adipokine secretion from visceral adipocytes. J. Clin. Biochem. Nutr. 2015, 56(2):149-154.
23. Geurts L., et al. Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota. Nat. Commun. 2015, 6:6495.
24. Cani P.D., Delzenne N.M. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr. Opin. Pharmacol. 2009, 9(6):737-743.
25. Carvalho B.M., et al. Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia 2012, 55(10):2823-2834.
26. Cani P.D., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57(6):1470-1481.
27. Brun P., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292(2):G518-G525.
28. Ding S., et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010, 5(8):e12191.
29. Ye D., Ma I., Ma T.Y. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290(3):G496-G504.
30. Cani P.D., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58(8):1091-1103.
31. Zhou X., et al. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. PLoS One 2014, 9(12):e115148.
32. Bergheim I., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 2008, 48(6):983-992.
33. Kavanagh K., et al. Dietary fructose induces endotoxemia and hepatic injury in calorically controlled primates. Am. J. Clin. Nutr. 2013, 98(2):349-357.
34. Spruss A., et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50(4):1094-1104.
35. Liu J., et al. Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. Clin. Exp. Pharmacol. Physiol. 2014, 41(7):482-488.
36. Wagnerberger S., et al. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J. Nutr. Biochem. 2013, 24(3):531-538.
37. Ritze Y., et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014, 9(1):e80169.
38. Harte A.L., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. (Lond.) 2010, 7:15.
39. Farhadi A., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008, 28(7):1026-1033.
40. Alisi A., et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2010, 50(6):645-649.
41. Jin R., et al. Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. Int. J. Hepatol. 2014, 2014:560620.
42. Giorgio V., et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig. Liver Dis. 2014, 46(6):556-560.
43. Miele L., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
44. Pendyala S., Walker J.M., Holt P.R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012, 142(5):1100-1101. (e2).
45. Erridge C., et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am. J. Clin. Nutr. 2007, 86(5):1286-1292.
46. Deopurkar R., et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010, 33(5):991-997.
47. Ghoshal S., et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J. Lipid Res. 2009, 50(1):90-97.
48. Ghanim H., et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009, 32(12):2281-2287.
49. Ley R.E., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444(7122):1022-1023.
50. Qin J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464(7285):59-65.
51. Turnbaugh P.J., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457(7228):480-484.
52. Frank D.N., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(34):13780-13785.
53. Balmer M.L., et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci. Transl. Med. 2014, 6(237):237ra66.
54. Moschen A.R., Kaser S., Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol. Metab. 2013, 24(11):537-545.
55. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489(7415):242-249.
56. Backhed F., et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(3):979-984.
57. Rabot S., et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010, 24(12):4948-4959.
58. Turnbaugh P.J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444(7122):1027-1031.
59. Claus S.P., et al. Colonization-induced host-gut microbial metabolic interaction. MBio 2011, 2(2):e00271-10. 10.1128/mBio.00271-10.
60. Le Roy T., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013, 62(12):1787-1794.
61. Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
62. Le Chatelier E., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500(7464):541-546.
63. Kirpich I.A., et al. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol. Clin. Exp. Res. 2012, 36(5):835-846.
64. Mouzaki M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58(1):120-127.
65. Wong V.W., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS One 2013, 8(4):e62885.
66. Hildebrandt M.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137(5):1716-1724. (e1-2).
67. Turnbaugh P.J., et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3(4):213-223.
68. Turnbaugh P.J., et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1(6):6ra14.
69. de Wit N., et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303(5):G589-G599.
70. Wu G.D., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334(6052):105-108.
71. Duncan S.H., et al. Human colonic microbiota associated with diet, obesity and weight loss. Int. J. Obes. (Lond.) 2008, 32(11):1720-1724.
72. David L.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505(7484):559-563.
73. Spencer M.D., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140(3):976-986.
74. Fava F., et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int. J. Obes. (Lond.) 2013, 37(2):216-223.
75. Buchwald H., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292(14):1724-1737.
76. Zhang H., et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(7):2365-2370.
77. Furet J.P., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010, 59(12):3049-3057.
78. Kong L.C., et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am. J. Clin. Nutr. 2013, 98(1):16-24.
79. Liou A.P., et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 2013, 5(178):178ra41.
80. Ravussin Y., et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring) 2012, 20(4):738-747.
81. Ley R.E. Obesity and the human microbiome. Curr. Opin. Gastroenterol. 2010, 26(1):5-11.
82. Cotillard A., et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500(7464):585-588.
83. Pachikian B.D., et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol. Nutr. Food Res. 2013, 57(2):347-359.
84. Everard A., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(22):9066-9071.
85. Ma X., Hua J., Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J. Hepatol. 2008, 49:821-830.
86. Li Z., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37(2):343-350.
87. Lee H.Y., et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim. Biophys. Acta 2006, 1761(7):736-744.
88. Yadav H., Jain S., Sinha P.R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23(1):62-68.
89. Wang Y., et al. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl. Microbiol. Biotechnol. 2009, 84(2):341-347.
90. Nardone G., et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299(3):G669-G676.
91. Xu R.Y., et al. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr. 2012, 50(1):72-77.
92. Endo H., et al. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One 2013, 8(5):e63388.
93. Ma Y.Y., et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J. Gastroenterol. 2013, 19(40):6911-6918.
94. Vajro P., et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 2011, 52(6):740-743.
95. Aller R., et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15(9):1090-1095.
96. Alisi A., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39(11):1276-1285.
97. Wong V.W., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013, 12(2):256-262.
98. Malaguarnera M., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57(2):545-553.
99. Eslamparast T., et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 2014, 99(3):535-542.